• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The relationship between tumor volume changes and serial plasma osteopontin detection during radical radiotherapy of non-small-cell lung cancer.非小细胞肺癌根治性放疗期间肿瘤体积变化与连续血浆骨桥蛋白检测之间的关系
Oncol Lett. 2016 Nov;12(5):3449-3456. doi: 10.3892/ol.2016.5104. Epub 2016 Sep 8.
2
Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer-results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group.局部晚期非小细胞肺癌根治性放化疗期间大体肿瘤体积的预后影响——来自 Young DEGRO 试验组的 NCT03055715 多中心队列研究的结果。
Strahlenther Onkol. 2021 May;197(5):385-395. doi: 10.1007/s00066-020-01727-4. Epub 2021 Jan 7.
3
Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer.非小细胞肺癌放疗中连续血浆骨桥蛋白测量的预后信息
BMC Cancer. 2014 Nov 21;14:858. doi: 10.1186/1471-2407-14-858.
4
Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.尿激酶型纤溶酶原激活物系统和骨桥蛋白在接受放疗的非小细胞肺癌患者中的共同检测对预后的影响及其与大体肿瘤体积的相关性。
Strahlenther Onkol. 2018 Jun;194(6):539-551. doi: 10.1007/s00066-017-1255-1. Epub 2018 Jan 16.
5
A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.非小细胞肺癌放射治疗中潜在的血浆缺氧标志物的初步研究。骨桥蛋白、碳酸酐酶 IX 和血管内皮生长因子。
Strahlenther Onkol. 2014 Mar;190(3):276-82. doi: 10.1007/s00066-013-0484-1. Epub 2013 Dec 11.
6
Perioperative changes in osteopontin and TGFβ1 plasma levels and their prognostic impact for radiotherapy in head and neck cancer.头颈部癌患者围手术期骨桥蛋白和转化生长因子β1血浆水平的变化及其对放疗的预后影响
BMC Cancer. 2017 Jan 3;17(1):6. doi: 10.1186/s12885-016-3024-4.
7
Predictive value of primary tumor volume change during concurrent chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer.不可切除 III 期非小细胞肺癌患者同期放化疗过程中原发肿瘤体积变化的预测价值。
Radiother Oncol. 2024 Sep;198:110383. doi: 10.1016/j.radonc.2024.110383. Epub 2024 Jun 13.
8
Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer.非小细胞肺癌切除术降低血浆骨桥蛋白水平。
J Clin Oncol. 2010 Feb 20;28(6):936-41. doi: 10.1200/JCO.2009.25.5711. Epub 2010 Jan 19.
9
Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.骨桥蛋白和血小板反应蛋白-1在促进原发性切除非小细胞肺癌的肿瘤侵袭性方面发挥相反作用。
BMC Cancer. 2016 Jul 15;16:483. doi: 10.1186/s12885-016-2541-5.
10
Dynamics of Heat Shock Protein 70 Serum Levels As a Predictor of Clinical Response in Non-Small-Cell Lung Cancer and Correlation with the Hypoxia-Related Marker Osteopontin.热休克蛋白70血清水平的动态变化作为非小细胞肺癌临床反应的预测指标及其与缺氧相关标志物骨桥蛋白的相关性
Front Immunol. 2017 Oct 18;8:1305. doi: 10.3389/fimmu.2017.01305. eCollection 2017.

引用本文的文献

1
Tumor volume change at radiation boost planning to estimate the response to chemoradiotherapy in stage III unresectable NSCLC (TORCH): a multicenter retrospective observational study.用于评估Ⅲ期不可切除非小细胞肺癌放化疗反应的放疗增敏计划时肿瘤体积变化(TORCH):一项多中心回顾性观察研究
Strahlenther Onkol. 2025 Mar 3. doi: 10.1007/s00066-025-02374-3.
2
Endocrine regulation and metabolic mechanisms of osteopontin in the development and progression of osteosarcoma, metastasis and prognosis.骨桥蛋白在骨肉瘤发生发展、转移和预后中的内分泌调节和代谢机制。
Front Endocrinol (Lausanne). 2023 Jan 13;13:1100063. doi: 10.3389/fendo.2022.1100063. eCollection 2022.
3
The value of plasma hypoxia markers for predicting imaging-based hypoxia in patients with head-and-neck cancers undergoing definitive chemoradiation.血浆缺氧标志物在预测接受根治性放化疗的头颈癌患者基于影像学的缺氧情况中的价值。
Clin Transl Radiat Oncol. 2022 Feb 21;33:120-127. doi: 10.1016/j.ctro.2022.02.008. eCollection 2022 Mar.
4
Hypoxia in Lung Cancer Management: A Translational Approach.肺癌治疗中的缺氧:一种转化医学方法。
Cancers (Basel). 2021 Jul 8;13(14):3421. doi: 10.3390/cancers13143421.
5
Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer-results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group.局部晚期非小细胞肺癌根治性放化疗期间大体肿瘤体积的预后影响——来自 Young DEGRO 试验组的 NCT03055715 多中心队列研究的结果。
Strahlenther Onkol. 2021 May;197(5):385-395. doi: 10.1007/s00066-020-01727-4. Epub 2021 Jan 7.
6
Osteopontin Regulates Endometrial Stromal Cell Migration in Endometriosis through the PI3K Pathway : Osteopontin Regulates Endometrial Cell Migration in Endometriosis.骨桥蛋白通过 PI3K 通路调控子宫内膜异位症中子宫内膜间质细胞的迁移:骨桥蛋白调控子宫内膜异位症中子宫内膜细胞的迁移。
Reprod Sci. 2021 Feb;28(2):435-446. doi: 10.1007/s43032-020-00301-8. Epub 2020 Sep 9.
7
Evaluation of kininogen 1, osteopontin and α-1-antitrypsin in plasma, bronchoalveolar lavage fluid and urine for lung squamous cell carcinoma diagnosis.评估血浆、支气管肺泡灌洗液和尿液中的激肽原1、骨桥蛋白和α-1抗胰蛋白酶用于肺鳞状细胞癌诊断的价值。
Oncol Lett. 2020 Apr;19(4):2785-2792. doi: 10.3892/ol.2020.11376. Epub 2020 Feb 6.
8
Osteopontin as a biomarker for osteosarcoma therapy and prognosis.骨桥蛋白作为骨肉瘤治疗和预后的生物标志物。
Oncol Lett. 2019 Mar;17(3):2592-2598. doi: 10.3892/ol.2019.9905. Epub 2019 Jan 8.
9
Is tumor volume reduction during radiotherapy prognostic relevant in patients with stage III non-small cell lung cancer?放疗过程中肿瘤体积缩小与 III 期非小细胞肺癌患者的预后相关吗?
J Cancer Res Clin Oncol. 2018 Jun;144(6):1165-1171. doi: 10.1007/s00432-018-2640-6. Epub 2018 Apr 5.
10
Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer : A systematic review.根治性放疗中 III 期非小细胞肺癌肿瘤体积及其变化的预测和预后价值:系统评价。
Strahlenther Onkol. 2018 Feb;194(2):79-90. doi: 10.1007/s00066-017-1221-y. Epub 2017 Oct 13.

本文引用的文献

1
The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.肿瘤体积及其变化对接受根治性同步放化疗的III期非小细胞肺癌患者生存的影响。
Radiat Oncol. 2014 Dec 13;9:283. doi: 10.1186/s13014-014-0283-6.
2
Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer.非小细胞肺癌放疗中连续血浆骨桥蛋白测量的预后信息
BMC Cancer. 2014 Nov 21;14:858. doi: 10.1186/1471-2407-14-858.
3
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.全球癌症发病与死亡:GLOBOCAN 2012 数据源、方法与主要模式。
Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.
4
A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.非小细胞肺癌放射治疗中潜在的血浆缺氧标志物的初步研究。骨桥蛋白、碳酸酐酶 IX 和血管内皮生长因子。
Strahlenther Onkol. 2014 Mar;190(3):276-82. doi: 10.1007/s00066-013-0484-1. Epub 2013 Dec 11.
5
Plasma osteopontin velocity differentiates lung cancers from controls in a CT screening population.血浆骨桥蛋白速度可区分 CT 筛查人群中的肺癌与对照者。
Cancer Biomark. 2012;12(4):177-84. doi: 10.3233/CBM-130306.
6
GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: subgroup analysis of the prospective randomized CHARTWEL trial.不同分割方案后 GTV 对非小细胞肺癌(NSCLC)局部区域控制的影响不同:前瞻性随机 CHARTWEL 试验的亚组分析。
Radiother Oncol. 2013 Mar;106(3):299-304. doi: 10.1016/j.radonc.2012.12.008. Epub 2013 Jan 17.
7
The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: a prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05).根治性放疗治疗非小细胞肺癌患者的肿瘤体积与生存的复杂关系:澳大利亚和新西兰放射肿瘤学组(TROG 99.05)的一项前瞻性观察性预后因素研究。
Radiother Oncol. 2013 Mar;106(3):305-11. doi: 10.1016/j.radonc.2012.12.003. Epub 2013 Jan 16.
8
Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer.局部晚期头颈部癌放化疗期间缺氧特异性 PET 成像的探索性前瞻性研究。
Radiother Oncol. 2012 Oct;105(1):21-8. doi: 10.1016/j.radonc.2012.08.019. Epub 2012 Sep 27.
9
Prognostic value of metabolic tumor volume and velocity in predicting head-and-neck cancer outcomes.代谢肿瘤体积和速度预测头颈部癌症结局的预后价值。
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1521-7. doi: 10.1016/j.ijrobp.2011.10.022. Epub 2012 Jan 21.
10
Tumor volume as a potential imaging-based risk-stratification factor in trimodality therapy for locally advanced non-small cell lung cancer.肿瘤体积作为局部晚期非小细胞肺癌三联疗法中潜在的基于影像学的风险分层因素。
J Thorac Oncol. 2011 May;6(5):920-6. doi: 10.1097/jto.0b013e31821517db.

非小细胞肺癌根治性放疗期间肿瘤体积变化与连续血浆骨桥蛋白检测之间的关系

The relationship between tumor volume changes and serial plasma osteopontin detection during radical radiotherapy of non-small-cell lung cancer.

作者信息

Ostheimer Christian, Schweyer Franziska, Reese Thomas, Bache Matthias, Vordermark Dirk

机构信息

Department of Radiation Oncology, Martin Luther University Halle-Wittenberg, D-06120 Halle (Saale), Germany.

出版信息

Oncol Lett. 2016 Nov;12(5):3449-3456. doi: 10.3892/ol.2016.5104. Epub 2016 Sep 8.

DOI:10.3892/ol.2016.5104
PMID:27900019
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5103967/
Abstract

The prognostic quality of increased osteopontin (OPN) plasma levels has been demonstrated for the chemotherapy and surgery of lung cancer. There is also evidence in the literature that tumor volume impacts prognosis in definitive radiotherapy (RT) of (lung) cancer. We previously demonstrated that elevated plasma levels of OPN before, and increasing OPN plasma levels after RT significantly correlate with survival and outcome after curative-intent RT of non-small-cell lung cancer (NSCLC). Tumor volume was also associated with prognosis. The present prospective clinical study investigated the prognostic interrelation of OPN plasma levels and tumor volume and their changes in the radical RT of NSCLC. We evaluated a subset of patients (n=27) with inoperable, non-metastasized NSCLC of the previously published patient collective. Patients were treated with radical radiochemotherapy (2 Gy ad 66 Gy). OPN plasma concentrations were determined by ELISA before (t0), at the end (t1), and 4 weeks after RT (t2). GTV was delineated PET- and CT-correlated before RT (GTV1) and after 40 Gy (GTV2). The course of OPN during and after RT and the change of GTV during RT was monitored over time and correlated with prognosis. Median GTV2 after 40 Gy (63 ml) was significantly lower than pre-RT GTV1 (90 ml, P<0.0001). Median OPN before (t0), at the end of (t1) and four weeks after RT (t2) was 846, 777 and 624 ng/ml and not significantly different. GTV significantly declined by 39 ml during RT (P<0.0001) and OPN non-significantly decreased by 56 ng/ml during (t0 to t1) and by 54 ng/ml after RT (t1 to t2). No correlations were determined between absolute OPN and GTV values or their relative changes during RT. In univariate analysis, only GTV2 significantly predicted overall survival (OS, P=0.03). In multivariate analysis, both OPN t1 (P<0.001) and GTV2 (P=0.001) remained significant predictors of OS. Relative OPN plasma level changes after (t1 to t2) and GTV changes during RT (GTV 1 to GTV 2) significantly predicted OS (P=0.02). The combination of absolute GTV values before RT (GTV1) and GTV changes during RT (GTV1 to 2) were significantly associated with OS in both uni- and multivariate analysis (P=0.03). The combination of absolute OPN plasma levels and their changes with GTV and its changes did not reach statistical significance. The lack of a significant correlation between OPN and GTV together with the finding that OPN and GTV remained independent predictors of survival outcome but were not associated with OS in combination supports the hypothesis that tumor volume (GTV) and OPN plasma levels (both their changes and absolute values) are not interrelated in terms of prognosis but do possess each parameter separately, a prognostic quality in the radical RT of NSCLC which justifies further prospective studies to validate these results.

摘要

骨桥蛋白(OPN)血浆水平升高对肺癌化疗和手术的预后价值已得到证实。文献中也有证据表明肿瘤体积对肺癌根治性放疗(RT)的预后有影响。我们之前证明,非小细胞肺癌(NSCLC)根治性放疗前血浆OPN水平升高以及放疗后血浆OPN水平升高与生存和预后显著相关。肿瘤体积也与预后相关。本前瞻性临床研究调查了NSCLC根治性放疗中OPN血浆水平与肿瘤体积的预后相关性及其变化。我们评估了先前发表的患者群体中一部分无法手术、无转移的NSCLC患者(n = 27)。患者接受根治性放化疗(2 Gy,共66 Gy)。在放疗前(t0)、结束时(t1)和放疗后4周(t2)通过酶联免疫吸附测定(ELISA)法测定OPN血浆浓度。在放疗前(GTV1)和40 Gy放疗后(GTV2)通过PET和CT相关性勾画大体肿瘤体积(GTV)。随时间监测放疗期间及放疗后OPN的变化过程以及放疗期间GTV的变化,并将其与预后相关联。40 Gy放疗后的中位GTV2(63 ml)显著低于放疗前的GTV1(90 ml,P < 0.0001)。放疗前(t0)、结束时(t1)和放疗后4周(t2)的中位OPN分别为846、777和624 ng/ml,差异无统计学意义。放疗期间GTV显著下降39 ml(P < 0.0001),OPN在放疗期间(t0至t1)非显著下降56 ng/ml,放疗后(t1至t2)下降54 ng/ml。未确定绝对OPN和GTV值之间或放疗期间它们的相对变化之间的相关性。单因素分析中,只有GTV2显著预测总生存期(OS,P = 0.03)。多因素分析中,OPN t1(P < 0.001)和GTV2(P = 0.001)仍然是OS的显著预测因素。放疗后(t1至t2)OPN血浆水平的相对变化和放疗期间GTV的变化(GTV 1至GTV 2)显著预测OS(P = 0.02)。放疗前绝对GTV值(GTV1)和放疗期间GTV的变化(GTV1至2)的组合在单因素和多因素分析中均与OS显著相关(P = 0.03)。绝对OPN血浆水平及其与GTV及其变化的组合未达到统计学意义。OPN与GTV之间缺乏显著相关性,以及OPN和GTV仍然是生存结果独立预测因素但两者组合与OS无关的发现支持了以下假设:肿瘤体积(GTV)和OPN血浆水平(两者的变化及其绝对值)在预后方面不相关,但每个参数单独具有预后价值,在NSCLC根治性放疗中这一价值证明有必要进行进一步的前瞻性研究以验证这些结果。